Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beckman Coulter, Lumigen make it official

This article was originally published in The Gray Sheet

Executive Summary

Beckman Coulter gains access to Lumigen's technology for immunochemical and other high-sensitivity testing via its $185 mil. acquisition, expected to close by Nov. 1. Having partnered with Lumigen for more than 10 years, Beckman Coulter has already drawn from the company's well; Lumigen's chemiluminescent chemistry is the cornerstone of Beckman Coulter's Access family of immunoassay systems, the Oct. 2 release says...

You may also be interested in...

Beckman Coulter/NexGen

Beckman Coulter agrees to buy the remaining 80% of NexGen Diagnostics, which was spun off from Lumigen when Beckman Coulter bought Lumigen in 2006 (1"The Gray Sheet" Oct. 9, 2006, In Brief). NexGen's assets are intellectual property unrelated to current products. The technology will "simplify and automate certain types of immunodiagnostics and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results," explains Richard Creager, VP of Beckman Coulter's Immunoassay Business Center. Beckman expects to take a charge of about $36 million for in-process R&D when the deal closes at the end of 2007

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts